PI
LCTX icon

PFG Investments’s Lineage Cell Therapeutics LCTX Stock Holding History

PFG Investments’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8K Sell
22,002
-200
-0.9% -$276 ﹤0.01% 1277
2026
Q1 		$35.1K Hold
22,202
– – ﹤0.01% 1167
2025
Q4 		$37.1K Buy
22,202
+1,000
+5% +$1.73K ﹤0.01% 1125
2025
Q3 		$35.8K Hold
21,202
– – ﹤0.01% 1090
2025
Q2 		$19.2K Hold
21,202
– – ﹤0.01% 1026
2025
Q1 		$9.57K Hold
21,202
– – ﹤0.01% 1010
2024
Q4 		$10.7K Hold
21,202
– – ﹤0.01% 1019
2024
Q3 		$19.2K Hold
21,202
– – ﹤0.01% 999
2024
Q2 		$21.1K Hold
21,202
– – ﹤0.01% 920
2024
Q1 		$31.4K Buy
21,202
+1,002
+5% +$1.14K ﹤0.01% 1011
2023
Q4 		$22K Hold
20,200
– – ﹤0.01% 478
2023
Q3 		$23.8K Hold
20,200
– – ﹤0.01% 506
2023
Q2 		$28.5K Hold
20,200
– – 0.01% 512
2023
Q1 		$30.3K Buy
+20,200
New +$28.2K 0.01% 485

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

PFG Investments's LCTX Position: Q2 2026 in Review

PFG Investments reduced its Lineage Cell Therapeutics (LCTX) stake by 0.9% in Q2 2026, selling an estimated $276 and leaving 22,002 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1277.

PFG Investments first reported a position in LCTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $37.1K in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • PFG Investments held 22,002 shares of Lineage Cell Therapeutics worth $28.8K as of Q2 2026.
  • PFG Investments sold 200 Lineage Cell Therapeutics shares in Q2 2026, an estimated $276.
  • Lineage Cell Therapeutics made up ﹤0.01% of PFG Investments's portfolio in Q2 2026, its #1277 holding.
  • PFG Investments first reported a position in Lineage Cell Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • PFG Investments's Lineage Cell Therapeutics position peaked at $37.1K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on PFG Investments's 13F filing for Q2 2026, filed 23 Jul 2026.